Twenty-four leading hemp professionals from all over the world gathered in Poland Friday and Saturday, Oct. 21-22, 2016 for the Hemp2020 Investment Summit. Most rolled in on Thursday for the pre-Summit reception in The Palace at Nakło — HempToday headquarters. We shared ideas and intelligence and heard the stories that only a group of hemp veterans with more than 140 years combined experience in the industry can tell — our Summit speakers.
Cannabidiol (CBD) is one of the non-psychotropic cannabinoids in industrial hemp. The last couple of years have seen growing interest in CBD. Cannabidiol not only has a plethora of beneficial health effects, but it also has no relevant side-effects, even when it is administered at high doses. CBD is increasingly used as a food supplement and in food supplement compositions, and ingredient in cosmetics, thereby generating new investments and creating employment in the cultivation and processing of hemp and hemp-derived products. Pharmaceutical products with CBD as an active ingredient have also been developed.
The European Industrial Hemp Association (EIHA) this week criticized “a few pharmaceutical companies” for leading a fight for legislation that would make CBD a prescription-only drug, on the heels of recent developments in Germany and the UK. The Association called for “urgent” action to overcome what it sees at present as “only a tenuous patchwork of CBD-regulation(s)” currently on the books.